Skip to main content
Beyfortus® logo

Downloadable Resources


Explore comprehensive downloadable resources and tools designed to aid you in improving Beyfortus® (nirsevimab-alip) uptake in your practice.

Tools for your practice

For parents

Give your baby an extra layer of protection against RSV when they need it most; RSV: Respiratory Syncytial Virus

RSV educational brochure

Educate parents on the basics of RSV disease and how Beyfortus can help protect their infant or child (<24 months of age).

Download in EnglishDownload in Spanish
Beyfortus® (nirsevimab-alip) RSV basics flyer thumbnail

RSV basics flyer

A brief flyer to educate parents on the basics of RSV disease and the protection offered by Beyfortus.

Download in EnglishDownload in Spanish

For nurses

Beyfortus® (nirsevimab-alip) parent conversation guide thumbnail

Conversation guide

Parent conversation guide

A guide designed to help nurses discuss common questions that parents may have regarding RSV lower respiratory tract disease and Beyfortus.

Beyfortus® (nirsevimab-alip) RSV general education poster thumbnail

Poster

RSV general education poster

An infographic poster that serves as a quick visual guide to understanding RSV risks and the role of Beyfortus.

Beyfortus® (nirsevimab-alip) RSV before the season poster thumbnail

Poster

RSV before the season poster

An infographic poster that serves as a quick reference guide, answering common questions about RSV and Beyfortus.

See how to address parental concerns around RSV immunization

For OB-GYNS

Consider these useful resources and materials for Beyfortus to help ensure a seamless integration into your practice.

Beyfortus® (nirsevimab-alip) parental counseling brochure for OB-GYNs thumbnail

OB-GYN brochure

Parental counseling brochure

A guide for educating parents on how Beyfortus can help protect newborns against RSV lower respiratory tract disease.

Beyfortus® (nirsevimab-alip) second pregnancy RSV guidance for OB-GYNs thumbnail

OB-GYN brochure

Second pregnancy RSV guidance

Guidance to help protect infants against RSV-LRTI if the mother has already received an RSV maternal vaccine during a previous pregnancy.

RSV-LRTI, respiratory syncytial virus lower respiratory tract infection.

Looking for information tailored to OB-GYNS?

Additional resources

Flyer

Second season immunization

A resource for identifying which infants might need additional protection for their second RSV season.

Brochure

What you need to know: Beyfortus and Abrysvo®

Guidance and information for protecting infants from RSV lower respiratory tract disease without immunity provided by maternal vaccination.

For additional copies of these materials, please reach out to your Sanofi Representative or call 1-800-VACCINE

Frequently asked questions

Order Beyfortus

Contact & sign up

Keep informed with email updates

Sign up to get the latest information on Beyfortus.

Reach out to our team for support

Request a Sanofi representative to learn more about Beyfortus.

EHR, electronic health record; FAQs, frequently asked questions; RSV, respiratory syncytial virus.

Important Safety Information

Contraindication

Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Warnings and Precautions

  • Hypersensitivity Reactions Including Anaphylaxis: Serious hypersensitivity reactions have been reported following Beyfortus administration. These reactions included urticaria, dyspnea, cyanosis, and/or hypotonia. Anaphylaxis has been observed with human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs and symptoms of anaphylaxis or other clinically significant hypersensitivity reactions occur, initiate appropriate treatment.
  • Use in Individuals with Clinically Significant Bleeding Disorders: As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

Indication

Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

  • Neonates and infants born during or entering their first RSV season.
  • Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Important Safety Information

Indication

MAT-US-2310577-v9.0-08/2026